Area of research
Oncology · Cancer Research
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, and Immune cells in cancer.
Empowering cancer research in Europe: the EUCAIM cancer imaging infrastructure
Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes
Ubiquitylation of MLKL at lysine 219 positively regulates necroptosis-induced tissue injury and pathogen clearance
An innate-like Vδ1 <sup>+</sup> γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer
Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells
Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer
Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node‐positive breast cancers
An immunologically relevant rodent model demonstrates safety of therapy using a tumour‐specific IgE
Genomic Evolution of Breast Cancer Metastasis and Relapse
RORγt+ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers
Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer
Microstructural models for diffusion MRI in breast cancer and surrounding stroma: an <i>ex vivo</i> study
Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or <i>BRCA1/2</i> breast cancer (CRUK/07/012)
Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis
Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value
Models of Breast Morphogenesis Based on Localization of Stem Cells in the Developing Mammary Lobule
c-Met PET Imaging Detects Early-Stage Locoregional Recurrence of Basal-Like Breast Cancer
IL15RA Drives Antagonistic Mechanisms of Cancer Development and Immune Control in Lymphocyte-Enriched Triple-Negative Breast Cancers
Aldehyde dehydrogenase and estrogen receptor define a hierarchy of cellular differentiation in the normal human mammary epithelium
Growth Hormone Is Secreted by Normal Breast Epithelium upon Progesterone Stimulation and Increases Proliferation of Stem/Progenitor Cells
Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium
Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium
Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles
Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control